FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a pharmaceutical composition for local application containing fusidic acid within the range of 1 wt % to 5 wt % and mometasone within the range of 0.05 wt % to 2 wt % and a pharmaceutically acceptable carrier to be applied in treating or preventing inflammatory dermatoses caused by a secondary bacterial infection in a patient.
EFFECT: invention provides effective elimination of secondary bacterial infections in dermatologic injuries.
11 cl, 8 ex, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL FORMULATIONS CONTAINING CORTICOSTEROIDS FOR TOPICAL APPLICATION | 2011 |
|
RU2568598C2 |
| COMBINED PHARMACEUTICAL COMPOSITION FOR EXTERNAL APPLICATION | 2018 |
|
RU2736940C2 |
| REMEDY FOR TREATING PRIMARY AND SECONDARY INFECTION SKIN DISEASES | 2006 |
|
RU2321409C1 |
| CREAM FOR MEDICAL APPLICATION CONTAINING FUSIDIC ACID PREPARED WITH USING SODIUM FUSIDATE AND CONTAINING BIOPOLYMER, AND METHOD FOR PREPARING IT | 2010 |
|
RU2537023C2 |
| AGENT FOR TREATING LOCAL ALLERGIC EXUDATIVE-INFLAMMATORY AND INFILTRATIVE-INFLAMMATORY SKIN PROCESSES | 2009 |
|
RU2417086C1 |
| USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | 2014 |
|
RU2666219C2 |
| METHOD FOR PREVENTION OF USING CORTICOSTEROIDS | 2009 |
|
RU2500408C2 |
| PHARMACEUTICAL COMPOSITION FOR ALLERGIC AND INFLAMMATORY SKIN DISEASES | 2009 |
|
RU2440108C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING SKIN DISEASES | 2013 |
|
RU2553600C2 |
| PHARMACEUTIC COMPOSITION FOR TREATMENT OF ALLERGIC AND INFLAMMATORY SKIN DISEASES | 2009 |
|
RU2420266C2 |
